---
title: "300562.SZ (300562.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300562.SZ/news.md"
symbol: "300562.SZ"
name: "300562.SZ"
parent: "https://longbridge.com/en/quote/300562.SZ.md"
datetime: "2026-05-21T09:22:38.031Z"
locales:
  - [en](https://longbridge.com/en/quote/300562.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300562.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300562.SZ/news.md)
---

# 300562.SZ (300562.SZ) — Related News

### [Tongxin Medical IPO: Domestic Artificial Heart "Gemini" Races for the Sci-Tech Innovation Board](https://longbridge.com/en/news/285812479.md)
*2026-05-09T12:06:11.000Z*
> Tongxin Medical and Core Medical are competing for listing on the Sci-Tech Innovation Board. The former was founded by r

### [Transtek: Change of Fundraising Investment Project](https://longbridge.com/en/news/284389519.md)
*2026-04-28T12:51:00.000Z*
> Transtek announced that the company will change the fundraising investment project, allocating 124 million yuan of the r

### [Transtek released its first-quarter performance, with a net profit attributable to the parent company of 32.0738 million yuan, an increase of 39.80%](https://longbridge.com/en/news/283827894.md)
*2026-04-23T12:05:57.000Z*
> Transtek released its Q1 2026 performance report, with operating revenue of 284 million yuan, a year-on-year increase of

### [Transtek: Net profit of 81.9991 million yuan in 2025, a year-on-year increase of 33.63%](https://longbridge.com/en/news/282204585.md)
*2026-04-09T13:23:56.000Z*
> Transtek announced that the operating revenue for 2025 is expected to be 986 million yuan, a year-on-year increase of 0.

### [Healthcare Industry Daily (04.01): Breakthroughs in Pharmaceutical Innovation](https://longbridge.com/en/news/281414019.md)
*2026-04-01T19:14:16.000Z*
> Sunshine Guojian Pharmaceutical expects a net profit growth of 311.49% year-on-year in 2025, with operating revenue reac

### [Tongxin Medical's prospectus update: Revenue in 2025 is expected to nearly double year-on-year, with overseas revenue accounting for more than half](https://longbridge.com/en/news/281276664.md)
*2026-04-01T01:07:16.000Z*
> Tongxin Medical updated its prospectus, expecting revenue to reach 213 million yuan in 2025, a year-on-year increase of 

### [Domestic Artificial Heart Duopoly Competition](https://longbridge.com/en/news/280407471.md)
*2026-03-25T03:36:39.000Z*
> This spring, two leading companies in the field of artificial hearts in China, Core Medical and Tongxin Medical, respect

### [Transtek: The large model application developed by the company focuses on cardiovascular and cerebrovascular diseases](https://longbridge.com/en/news/275530491.md)
*2026-02-11T00:47:05.000Z*
> On February 11th, Transtek stated on the interactive platform that the large model application developed by the company 

### [BLUE SAIL MEDICAL's cardiovascular business turns a profit, innovative products accelerate volume growth](https://longbridge.com/en/news/274311137.md)
*2026-01-30T12:37:13.000Z*
> BLUE SAIL MEDICAL announced in its 2025 annual performance forecast that the cardiovascular and cerebrovascular division